NCT00446446View on ClinicalTrials.gov

PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

October 30, 2007

Primary Completion Date

December 15, 2010

Study Completion Date

November 29, 2017

Conditions
CancerCarcinomaHead and Neck CancerMetastasesMetastatic CancerMetastatic or Recurrent Squamous Cell Carcinoma of Head and NeckOncologySquamous Cell CarcinomaTumors
Interventions
DRUG

Panitumumab

Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days.

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00446446 - PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) | Biotech Hunter | Biotech Hunter